合并深静脉血栓形成对卵巢癌预后的影响

Abstract
Figure/Table
References (22)
Related Citation (12)

Download: PDF (445 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate whether the combination of deep venous thrombosis (DVT) in the early diagnosis of ovarian cancer has an effect on its prognosis, and to study whether there was a difference in prognosis between symptomatic DVT and asymptomatic DVT combined with ovarian cancer. Methods Sixty-five patients with ovarian cancer (including primary peritoneal cancer and fallopian tube cancer) hospitalized from January 2008 and December 2015 in Jingzhou Center Hospital were selected and devided into DVT group with 15 cases and no DVT group with 50 cases. The clinical, pathological and survival data of the two groups were compared. Results Median overall-survival of DVT group was significantly shorter than no DVT group (21.7 months vs. 40.0 months) (P = 0.001). There was no statistical significance between DVT group and no DVT group in median progression-free survival (17.2 months vs. 28.7 months) (P = 0.361). Median overall-survival of symptomatic DVT group was significantly shorter than asymptomatic DVT group (21.5 months vs. 37.9 months) (P = 0.010). There were no significant differences between no DVT group and asymptomatic DVT group (P = 0.069), median overall-survival of no DVT group was significantly longer than symptomatic DVT group, the difference was satistically significant (P = 0.008). Conclusion Complicating deep venous thrombosis at time of diagnosis is an adverse prognostic factor in ovarian cancer. It mainly reflected in complicating symptomatic DVT decreasing overall survival of ovarian cancer patients.

Key words： Ovarian cancer Deep venous thrombosis Survival Symptomatic

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Yue1 TANG Dong2

Cite this article:

HU Yue1 TANG Dong2. The effect of complicating deep venous thrombosis on the prognosis of ovarian cancer[J]. 中国医药导报, 2018, 15(8): 96-99.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I8/96

[1] 于玲，姜桂春.Orem自护理论在老年肺癌患者术后静脉血栓栓塞症预防中的应用[J].中国医药导报 2017，14（11）：144-147.
[2] 杨静宜，宋永平.恶性肿瘤相关静脉血栓栓塞症研究进展[J].中华血液学杂志，2014，35（10）：957-960.
[3] Hisada Y，Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis [J]. Blood，2017，130（13）：1499-1506.
[4] Swier N，Versteeg HH. Reciprocal links between venous thromboembolism，coagulation factors and ovarian cancer progression [J]. Thromb Res，2017，150：8-18.
[5] Mege D，Mezouar S，Dignat-George F，et al. Microparticles and cancer thrombosis in animal models [J]. Thromb Res，2016，140：S21-S26.
[6] Abu SF，Norris L，O'Toole S，et al. Venous thromboembolism in ovarian cancer：incidence，risk factors and impact on survival [J]. Eur J Obstet Gynecol Reprod Biol 2013，170（1）：214-218.
[7] 冯征，温灏，吴小华.卵巢癌患者血液高凝状态临床研究进展[J].中国癌症杂志，2015，25（3）：231-234.
[8] Schunemann HJ，Ventresca M，Crowther M，et al. Use of heparins in patients with cancer： individual participant data meta-analysis of randomised trials study protocol [J]. BMJ Open，2016，6（4）：e10569.
[9] 张成欢，刘云.Autar血栓风险评估量表评估骨科关节置换患者深静脉血栓形成风险的研究[J].医学研究生学报，2017，30（9）：968-972.
[10] Arora M，Wun T. Adverse impact of venous thromboembolism on patients with cancer [J]. Semin Thromb Hemost，2014， 40（3）：313-318.
[11] Riondino S，Guadagni F，Formica V，et al. Gender Differences in Cancer-associated Venous Thromboembolism [J]. Curr Med Chem，2017，24（24）：2589-2601.
[12] Kumar A，Hurtt CC，Cliby WA，et al. Concomitant venous thromboembolism at the time of primary EOC diagnosis： Perioperative outcomes and survival analyses [J]. Gynecol Oncol，2017，147（3）：514-520.
[13] Awkar N，Amireh S，Rai S，et al. Association between Level of Tumor Markers and Development of VTE in Patients with Pancreatic，Colorectal and Ovarian Ca： Retrospective Case- Control Study in Two Community Hospitals [J]. Pathol Oncol Res，2018,24（2）：283-287.
[14] Chavan DM，Huang Z，Song K，et al. Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer [J]. Medicine（Baltimore），2017，96（42）：e7935.
[15] Falanga A，Schieppati F，Russo D. Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer [J]. Semin Thromb Hemost，2015，41（7）：756-764.
[16] Chen LM，Wang W，Lee JC，et al. Thrombomodulin mediates the progression of epithelial ovarian cancer cells [J]. Tumour Biol，2013，34（6）：3743-3751.
[17] Yuan L，Liu X. Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism [J]. Mol Med Rep，2015，11（4）：2449-2458.
[18] Gunderson CC，Thomas ED，Slaughter KN，et al. The survival detriment of venous thromboembolism with epithelial ovarian cancer [J]. Gynecol Oncol，2014，134（1）：73-77.
[19] Diaz ES，Walts AE，Karlan BY，et al. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival [J]. Gynecol Oncol，2013，131（3）：541-545.
[20] Cohen JG，Prendergast E，Geddings JE，et al. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer [J]. Gynecol Oncol，2017，146（1）：146-152.
[21] Abu SF，Norris L，O'Toole S，et al. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer-relationship with venous thrombosis risk [J]. Thromb Res，2013，132（5）：627-634.
[22] Oranratanaphan S，Termrungruanglert W，Khemapech N. Incidence and Clinical Characteristic of Venous Thromboembolism in Gynecologic Oncology Patients attending King Chulalongkorn Memorial Hospital over a 10 Year Period [J]. Asian Pac J Cancer Prev，2015，16（15）：6705-6709.